Abstracts | 39 patients with schizophrenia or bipolar disorder. Quality of life (QoL) is the general feelings of well-being of individuals. In this study, we measured the QoL in patients with schizophrenia or bipolar disorder who were receiving LAI treatment. Methods: 434 patients with schizophrenia and 42 patients with bipolar disorder received LAI treatment for at least 6 months regularly at Taipei City Psychiatric Center were administered with Brief World Health Organization's Quality of Life (WHOQoL), Chinese Health Questionnaire (CHQ), Subjective Well-being under Neuroleptics (SWN) and Social Performance scale (PSP) in a cross-sectional interview. Results: The duration of LAI treatment was 8.6 ± 8.9 years for schizophrenia and 5.5 ± 7.5 years for bipolar disorder, with total scores of WHOQoL 50.4 ± 8.9 and 52.1 ± 8.9, respectively (Norm: 56.1 in Taiwan). There was no difference in WHOQOL, CHQ between the two groups, while the bipolar patients had slightly higher SWN (81.8 ± vs 13.278.1 ± 12.2, P= 0.060) and significant PSP scores (74.6 ± 5.8 vs 71.0 ± 5.9, P<0.001). The Frequency of hospitalization (times/year) were significantly decreased after LAI treatment in schizophrenia (0.26 ± 0.42 to 0.09 ± 0.24) and bipolar disorder (0.56 ± 0.67 to 0.15 ± 0.39). Conclusions: LAI treatment can efficaciously prevent the relapse of psychotic or mood episodes in patients with poor adherence to medications. Patients with bipolar disorders reported a slightly higher satisfaction, in terms of SWN and PSP, but not QoL and CHQ, than patients with schizophrenia. These results suggest that patients with schizophrenia or bipolar disorder can have an acceptable level of QoL when they are under a regular adherence to medications.
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Treatment successful rate and efficacy of Paliperidone ER in patients with acute schizophrenia Yi-hsing Chen, Chang Bing Show Chwan Memorial Hospital, Taiwan Abstract Objective: The treatment successful rate is one of the major concerns in acute phase of schizophrenia. This study aimed to evaluate the treatment successful rate and efficacy of Paliperidone ER in acute schizophrenia and schizoaffective disorder patients. Method: Retrospective 12 months patients who received Paliperidone ER treatment after admitted to acute ward as first-line antipsychotic were enrolled in this study. The primary endpoint was Clinical Global Impression-Severity (CGI-S) score. Secondary endpoints included dosage distributed rate of Paliperidone ER while admission and discharged, combined medication (anticholinergics) situation, duration dates of admission. Treatment successful was defined to change CGI-S score more than 1 point. Combined other antipsychotics were not allowed. . Results: 40 Patients enrolled. Treatment successful rate is 86%. Mean CGI-S score changed from 4.77 to 3.2. Admission dosage distributed rate is 9mg 39%; 12mg 33%, discharge dosage distributed rate is 9mg 28%; 12mg 44%. Anticholinergics were frequently needed to prevent EPS symptoms, but additional dosage didn't need. Average duration date of admission is 33.6 days.
Conclusion:
In acute ward we need to control patient's symptoms in short time. We may not have too much time to try the second antipsychotic during admission. In this study we find that Paliperidone ER can offer enough successful rate when first-line use. Maybe start with optimal dosage (9~12mg) can be more ensured highest successful treatment rate, and seems safe when higher dosage usage. We expect Paliperidone ER can effectively help patient improve during acute stage schizophrenia.
